It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.

So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.

One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Cytokinetics, Incorporated (CYTK Quick QuoteCYTK - Free Report) . This Medical-Biomedical/Genetics industry stock has actually seen estimates rise over the past month for the current fiscal year by about 90%. But that is not yet reflected in its price, as the stock gained only 1.1% over the same time frame.

You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 87.3%, which should ultimately translate into price appreciation.

And if this isn’t enough, CYTK currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Cytokinetics. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for CYTK and that now might be an interesting buying opportunity.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>